Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0000950170-25-057665
Filing Date
2025-04-24
Accepted
2025-04-24 07:05:44
Documents
19
Period of Report
2025-06-05

Document Format Files

Seq Description Document Type Size
1 DEF 14A amlx-20250424.htm   iXBRL DEF 14A 1260452
2 GRAPHIC img112360252_0.jpg GRAPHIC 103455
3 GRAPHIC img112360252_1.jpg GRAPHIC 103455
4 GRAPHIC img112360252_2.jpg GRAPHIC 325692
5 GRAPHIC img112360252_3.jpg GRAPHIC 312776
6 GRAPHIC img112360252_4.jpg GRAPHIC 244139
7 GRAPHIC img112360252_5.jpg GRAPHIC 257007
  Complete submission text file 0000950170-25-057665.txt   5466367

Data Files

Seq Description Document Type Size
8 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT amlx-20250424.xsd EX-101.SCH 42909
21 EXTRACTED XBRL INSTANCE DOCUMENT amlx-20250424_htm.xml XML 363033
Mailing Address 43 THORNDIKE STREET CAMBRIDGE MA 02141
Business Address 43 THORNDIKE STREET CAMBRIDGE MA 02141 617-683-0917
Amylyx Pharmaceuticals, Inc. (Filer) CIK: 0001658551 (see all company filings)

EIN.: 464600503 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-41199 | Film No.: 25863551
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)